未登录

X

Xiaodong Liu

School of Pharmacy

H指数:33

被引数:3,811

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acute liver failure-induced arginine deficiency impairs blood-brain barrier via inhibiting mTORC1-S6K1/4EBP1 pathway and inducing autophagy

急性肝功能衰竭诱导的精氨酸缺乏通过抑制mTORC1-S6K1/4EBP1通路和诱导自噬来损害血脑屏障。

Cell Death & Disease

IF9.6

2025-11-170

OAAI

Ecological Resilience and Sustainable Development: Dynamic Assessment and Evolution Mechanisms of Landscape Patterns and Ecotourism Suitability in the Yangtze River Delta Region

生态韧性及可持续发展：长江三角洲地区景观格局与生态旅游适宜性的动态评估与演化机制

Sustainability 2025, Vol. 17, Page 7706

IF3.3

2025-08-280

OA

Lightning-ignited wildfire prediction in the boreal forest of northeast China

东北中国针叶林地区的雷击野火预测

Global and Planetary Change

IF4

2025-06-200

PRE

Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models

IF5.5

2025-02-070

OAAI

Identification of human cranio-maxillofacial skeletal stem cells for mandibular development

人类颅颌面骨骼干细胞在下颌骨发育中的鉴定

SCIENCE ADVANCES

IF12.5

2025-01-031

PRE

Prediction of SPT-07A Pharmacokinetics in Rats, Dogs, and Humans Using a Physiologically-Based Pharmacokinetic Model and In Vitro Data

IF5.5

2024-12-150

OAAI

Neurons enhance blood-brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion

IF0

2024-10-301

OA

Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice

ACTA PHARMACOLOGICA SINICA

IF8.4

2024-10-290

PRE

Bile duct ligation impairs visual acuity in rats by ammonia- and bilirubin-induced retinal degeneration

ACTA PHARMACOLOGICA SINICA

IF8.4

2024-09-180

PRE

Indoxyl sulphate-TNFα axis mediates uremic encephalopathy in rodent acute kidney injury

硫酸吲哚酚-tnf α 轴介导啮齿动物急性肾损伤中的尿毒症脑病

ACTA PHARMACOLOGICA SINICA

IF8.4

2024-04-081

PRE

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

IF5.5

2024-02-051

OAAI

Assessment of Quinidine-Induced Torsades de Pointes Risks Using a Whole-Body Physiologically Based Pharmacokinetic Model Linked to Cardiac Ionic Current Inhibition

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-01-070

PRE

Hepatic retinaldehyde deficiency is involved in diabetes deterioration by enhancing PCK1-and G6PC-mediated gluconeogenesis

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-09-018

OAAI

Effect of an inactivated coronavirus disease 2019 vaccine, CoronaVac, on blood coagulation and glucose: a randomized, controlled, open-label phase IV clinical trial

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-05-310

OAAI

Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms

PHARMACEUTICAL RESEARCH

IF4.3

2023-05-240

PRE

Bile duct ligation increased dopamine levels in the cerebral cortex of rats partly due to induction of tyrosine hydroxylase

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2023-02-136

OA

Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-01-015

OAAI

Prediction of drug pro-arrhythmic cardiotoxicity using a semi-physiologically based pharmacokinetic model linked to cardiac ionic currents inhibition

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2022-12-014

PRE

Predictors of Adverse Events Among Chronic Total Occlusion Patients Undergoing Successful Percutaneous Coronary Intervention and Medical Therapy

CLINICAL INTERVENTIONS IN AGING

IF3.7

2021-10-015

OAAI

Bile Duct Ligation Upregulates Expression and Function of L-Amino Acid Transporter 1 at Blood-Brain Barrier of Rats via Activation of Aryl Hydrocarbon Receptor by Bilirubin

IF3.9

2021-09-263

OAAI